Selected bibliography
- Cairncross JG, Macdonald D, Ludwin S et al. Chemother- apy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013–2021.
- Cairncross JG, Ueki K, Zlatesou MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473–1479.
- Chang SM, Kuhn JG, Robins HI et al. A phase II study of paclitaxel (Taxol) using different doses depending on the concomitant use of anticonvulsants in patients with recurrent malignant glioma. Cancer 2001; 91: 417–422.
- Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis in three Radiation Therapy Oncology Group malig- nant glioma trials. J Natl Cancer Inst 1993; 26: 704–710.
- Friedman LM, Furberg, CD, DeMets DL. Fundamentals of Clinical Trials. 3rd. ed. Springer. 1998.
- Kaplan RS. Complexities, pitfalls, and strategies for evaluation of brain tumor therapies. Curr Opin Oncol 1998; 10: 175–178.
- Macdonald DR, Cascino TL, Schold SC et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–1280.
- Pazdur R. Response rates, survival, and chemotherapy trials. J Natl Cancer Inst 2000; 92: 1552–1553.
- Perry JR, DeAngelis LM, Schold SC Jr et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997; 49: 912–917.